News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
458,043 Results
Type
Article (48779)
Company Profile (70)
Press Release (409194)
Multimedia
Podcasts (34)
Webinars (10)
Section
Business (125529)
Career Advice (684)
Deals (18492)
Drug Delivery (62)
Drug Development (55777)
Employer Resources (66)
FDA (12941)
Job Trends (9583)
News (217150)
Policy (21232)
Tag
Academia (2788)
Academic (1)
Accelerated approval (4)
Adcomms (11)
Allergies (81)
Alliances (31922)
ALS (68)
Alzheimer's disease (1001)
Antibody-drug conjugate (ADC) (76)
Approvals (12997)
Artificial intelligence (191)
Autoimmune disease (10)
Automation (7)
Bankruptcy (151)
Best Places to Work (7737)
BIOSECURE Act (19)
Biosimilars (43)
Biotechnology (49)
Bladder cancer (65)
Brain cancer (21)
Breast cancer (221)
Cancer (1656)
Cardiovascular disease (132)
Career advice (620)
Career pathing (18)
CAR-T (86)
Cell therapy (255)
Cervical cancer (17)
Clinical research (46131)
Collaboration (530)
Company closure (1)
Compensation (142)
Complete response letters (9)
COVID-19 (2075)
CRISPR (20)
C-suite (217)
Cystic fibrosis (52)
Data (1815)
Decentralized trials (2)
Denatured (21)
Depression (34)
Diabetes (195)
Diagnostics (4163)
Digital health (11)
Diversity (8)
Diversity, equity & inclusion (21)
Drug discovery (63)
Drug pricing (58)
Drug shortages (22)
Duchenne muscular dystrophy (66)
Earnings (40200)
Editorial (27)
Employer branding (8)
Employer resources (60)
Events (58612)
Executive appointments (644)
FDA (14046)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (496)
Gene editing (62)
Generative AI (13)
Gene therapy (178)
GLP-1 (484)
Government (3443)
Grass and pollen (3)
Guidances (100)
Healthcare (13843)
Huntington's disease (11)
IgA nephropathy (18)
Immunology and inflammation (49)
Indications (22)
Infectious disease (2166)
Inflammatory bowel disease (92)
Inflation Reduction Act (4)
Influenza (40)
Intellectual property (61)
Interviews (72)
IPO (7756)
IRA (21)
Job creations (2144)
Job search strategy (573)
Kidney cancer (8)
Labor market (19)
Layoffs (202)
Leadership (5)
Legal (4096)
Liver cancer (63)
Lung cancer (251)
Lymphoma (114)
Machine learning (5)
Management (21)
Manufacturing (155)
MASH (60)
Medical device (13234)
Medtech (13237)
Mergers & acquisitions (11057)
Metabolic disorders (490)
Multiple sclerosis (61)
NASH (12)
Neurodegenerative disease (62)
Neuropsychiatric disorders (10)
Neuroscience (1388)
NextGen: Class of 2025 (4636)
Non-profit (3385)
Now hiring (18)
Obesity (237)
Opinion (91)
Ovarian cancer (63)
Pain (72)
Pancreatic cancer (64)
Parkinson's disease (104)
Partnered (13)
Patents (140)
Patient recruitment (95)
Peanut (43)
People (46404)
Pharmaceutical (17)
Pharmacy benefit managers (12)
Phase I (13745)
Phase II (20101)
Phase III (15772)
Pipeline (859)
Policy (91)
Postmarket research (2023)
Preclinical (5269)
Press Release (35)
Prostate cancer (83)
Psychedelics (19)
Radiopharmaceuticals (177)
Rare diseases (219)
Real estate (3624)
Recruiting (26)
Regulatory (15290)
Reports (18)
Research institute (2081)
Resumes & cover letters (64)
Rett syndrome (3)
RNA editing (2)
RSV (20)
Schizophrenia (55)
Series A (84)
Series B (59)
Service/supplier (3)
Sickle cell disease (31)
Special edition (4)
Spinal muscular atrophy (111)
Sponsored (18)
Startups (2584)
Stomach cancer (9)
Supply chain (41)
Tariffs (18)
The Weekly (13)
Vaccines (468)
Venture capitalists (16)
Weight loss (160)
Women's health (21)
Worklife (5)
Date
Today (76)
Last 7 days (555)
Last 30 days (1831)
Last 365 days (20706)
2025 (7326)
2024 (22424)
2023 (25975)
2022 (34744)
2021 (37640)
2020 (36778)
2019 (32898)
2018 (25084)
2017 (22266)
2016 (21866)
2015 (25600)
2014 (19721)
2013 (17634)
2012 (18673)
2011 (18826)
2010 (17003)
Location
Africa (504)
Alabama (22)
Alaska (4)
Arizona (131)
Arkansas (11)
Asia (30911)
Australia (5197)
California (3652)
Canada (1377)
China (462)
Colorado (184)
Connecticut (198)
Delaware (129)
Europe (61412)
Florida (617)
Georgia (151)
Idaho (37)
Illinois (417)
India (18)
Indiana (247)
Iowa (3)
Japan (133)
Kansas (78)
Kentucky (13)
Louisiana (8)
Maine (32)
Maryland (695)
Massachusetts (2526)
Michigan (127)
Minnesota (294)
Mississippi (2)
Missouri (58)
Montana (21)
Nebraska (18)
Nevada (43)
New Hampshire (62)
New Jersey (1245)
New Mexico (15)
New York (1090)
North Carolina (680)
North Dakota (5)
Northern California (1603)
Ohio (157)
Oklahoma (8)
Oregon (24)
Pennsylvania (955)
Puerto Rico (7)
Rhode Island (28)
South America (682)
South Carolina (24)
Southern California (1401)
Tennessee (85)
Texas (627)
United States (14874)
Utah (127)
Virginia (92)
Washington D.C. (49)
Washington State (304)
West Virginia (3)
Wisconsin (45)
458,043 Results for "zhejiang chinese medical university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ADCs
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu
With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.
January 22, 2025
·
2 min read
·
Tristan Manalac
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
PharmaBlock Sciences, Inc., a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API GMP facility at its Zhejiang manufacturing site.
December 26, 2023
·
1 min read
Cancer
Summit, Akeso’s Keytruda Challenger Wins Chinese OK as US Approval Questions Linger
With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the air.
April 28, 2025
·
3 min read
·
Tristan Manalac
Earnings
BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing
BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.
May 5, 2025
·
3 min read
·
Tristan Manalac
China
Bayer Jumps on Chinese Partnership Train with Oncology Deal
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.
March 26, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
March 31, 2025
·
5 min read
Press Releases
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
April 22, 2025
·
10 min read
Press Releases
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
March 18, 2025
·
5 min read
IPO
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
January 22, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Merck Commits Nearly $2B for Oral Lipid-Lowering Drug from Chinese Biotech
Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk of adverse cardiovascular outcomes.
March 25, 2025
·
2 min read
·
Tristan Manalac
1 of 45,805
Next
